Antisense conjugates for decreasing expression of DMPK
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
A61K-047/68
A61K-031/7088
C07K-016/44
C12N-015/113
A61J-001/14
A61K-031/713
C07K-016/28
A61K-047/69
출원번호
US-0474003
(2017-03-30)
등록번호
US-10238753
(2019-03-26)
발명자
/ 주소
Armstrong, Dustin D.
출원인 / 주소
Valerion Therapeutics, LLC
대리인 / 주소
Warren, Esq., Lisa M.
인용정보
피인용 횟수 :
0인용 특허 :
101
초록▼
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugate
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.
대표청구항▼
1. A conjugate comprising an antisense oligonucleotide that hybridizes to a DMPK transcript; andan antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13,
1. A conjugate comprising an antisense oligonucleotide that hybridizes to a DMPK transcript; andan antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13, or wherein the antibody or antigen binding fragment comprises a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 14. 2. The conjugate claim 1, wherein the antibody or antigen binding fragment is a chimeric, humanized, or fully human antibody or antigen binding fragment. 3. The conjugate of claim 1, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13 and a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 14, or a humanized variant thereof. 4. The conjugate of claim 1, wherein the antibody or antigen binding fragment comprises a VH CDR1 having the amino acid sequence of SEQ ID NO: 16;a VH CDR2 having the amino acid sequence of SEQ ID NO: 17;a VH CDR3 having the amino acid sequence of SEQ ID NO: 18;a VL CDR1 having the amino acid sequence of SEQ ID NO: 19;a VL CDR2 having the amino acid sequence of SEQ ID NO: 20; anda VL CDR3 having the amino acid sequence of SEQ ID NO: 21. 5. The conjugate of claim 1, wherein the antisense oligonucleotide hybridizes to CUG repeats to at least a portion of the 3′ UTR of a DMPK transcript. 6. The conjugate of claim 1, wherein the antisense oligonucleotide hybridizes to any one of SEQ ID NOs: 24-27. 7. The conjugate of claim 1, wherein the antisense oligonucleotide is capable, upon hybridization to its target sequence, of mediating RNase H-mediated degradation. 8. The conjugate of claim 1, wherein the antisense oligonucleotide prevents proteins or nucleic acids from binding to at least a portion of the 3′UTR of a DMPK transcript. 9. The conjugate of claim 1, wherein the antisense oligonucleotide prevents a protein or nucleic acid from binding to any one of SEQ ID NOs: 24-27. 10. The conjugate of claim 1, wherein the antisense oligonucleotide comprises two wing portions, each of which flank the central portion. 11. The conjugate of claim 10, wherein each of the two wing portions comprises at least 3 nucleotides. 12. The conjugate of claim 10, wherein each of the two wing portions is of differing length. 13. The conjugate of claim 10, wherein each of the two wing portions comprises at least 3 nucleotides modified to increase stability or specificity of the oligonucleotide. 14. The conjugate of claim 13, wherein each of the two wing portions comprises unmodified and/or modified nucleotides. 15. The conjugate of claim 1, wherein the ratio of antisense oligonucleotide conjugated per antibody or antigen binding fragment is 1:1. 16. The conjugate of claim 1, wherein the conjugate is capable of penetrating muscle cells. 17. The conjugate of claim 1, wherein the conjugate further comprises a muscle blind polypeptide (MBNL1), or a functional fragment thereof comprising all four zinc finger motifs, interconnected to the antibody or antigen fragment thereof. 18. A method of treating myotonic dystrophy, comprising administering to a patient in need thereof a conjugate of claim 1. 19. A method of promoting entry into muscle cells, comprising contacting cells or administering to a patient a conjugate of claim 1. 20. A conjugate comprising: an antisense oligonucleotide that hybridizes to a DMPK transcript; andan antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof. 21. The conjugate of claim 20, wherein the antibody or antigen binding fragment is a chimeric, humanized, or fully human antibody or antigen binding fragment. 22. The conjugate of claim 20, wherein the antibody or antigen binding fragment comprises a VH CDR1 having the amino acid sequence of SEQ ID NO: 16;a VH CDR2 having the amino acid sequence of SEQ ID NO: 17;a VH CDR3 having the amino acid sequence of SEQ ID NO: 18;a VL CDR1 having the amino acid sequence of SEQ ID NO: 19;a VL CDR2 having the amino acid sequence of SEQ ID NO: 20; anda VL CDR3 having the amino acid sequence of SEQ ID NO: 21. 23. The conjugate of claim 20, wherein the antisense oligonucleotide hybridizes to CUG repeats to at least a portion of the 3′ UTR of a DMPK transcript. 24. The conjugate of claim 20, wherein the antisense oligonucleotide hybridizes to any one of SEQ ID NOs: 24-27. 25. The conjugate of claim 20, wherein the antisense oligonucleotide is capable, upon hybridization to its target sequence, of mediating RNase H-mediated degradation. 26. The conjugate of claim 20, wherein the antisense oligonucleotide prevents proteins or nucleic acids from binding to at least a portion of the 3′UTR of a DMPK transcript. 27. The conjugate of claim 20, wherein the antisense oligonucleotide prevents a protein or nucleic acid from binding to any one of SEQ ID NOs: 24-27. 28. The conjugate of claim 20, wherein the antisense oligonucleotide comprises two wing portions, each of which flank the central portion. 29. The conjugate of claim 28, wherein each of the two wing portions comprises at least 3 nucleotides. 30. The conjugate of claim 28, wherein each of the two wing portions is of differing length. 31. The conjugate of claim 28, wherein each of the two wing portions comprises at least 3 nucleotides modified to increase stability or specificity of the oligonucleotide. 32. The conjugate of claim 31, wherein each of the two wing portions comprises unmodified and/or modified nucleotides. 33. The conjugate of claim 20, wherein the ratio of antisense oligonucleotide conjugated per antibody or antigen binding fragment is 1:1. 34. The conjugate of claim 20, wherein the conjugate is capable of penetrating muscle cells. 35. The conjugate of claim 20, wherein the conjugate further comprises a muscle blind polypeptide (MBNL1), or a functional fragment thereof comprising all four zinc finger motifs, interconnected to the antibody or antigen fragment thereof. 36. A method of treating myotonic dystrophy, comprising administering to a patient in need thereof a conjugate of claim 20. 37. A method of promoting entry into muscle cells, comprising contacting cells or administering to a patient a conjugate of claim 20. 38. A conjugate comprising an antisense oligonucleotide that hybridizes to a DMPK transcript; andan antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprisesa VH CDR1 having the amino acid sequence of SEQ ID NO: 16;a VH CDR2 having the amino acid sequence of SEQ ID NO: 17;a VH CDR3 having the amino acid sequence of SEQ ID NO: 18;a VL CDR1 having the amino acid sequence of SEQ ID NO: 19;a VL CDR2 having the amino acid sequence of SEQ ID NO: 20; anda VL CDR3 having the amino acid sequence of SEQ ID NO: 21. 39. The conjugate of claim 38, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13, or wherein the antibody or antigen binding fragment comprises a light chain variable domain comprising an amino acid sequence at least 95% identical to SEQ ID NO: 14. 40. The conjugate of claim 38, wherein the antibody or antigen binding fragment comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 14, or a humanized variant thereof. 41. The conjugate of claim 38, wherein the antibody or antigen binding fragment is a chimeric, humanized, or fully human antibody or antigen binding fragment. 42. The conjugate of claim 38, wherein the antisense oligonucleotide hybridizes to CUG repeats to at least a portion of the 3′ UTR of a DMPK transcript. 43. The conjugate of claim 38, wherein the antisense oligonucleotide hybridizes to any one of SEQ ID NOs: 24-27. 44. The conjugate of claim 38, wherein the antisense oligonucleotide is capable, upon hybridization to its target sequence, of mediating RNase H-mediated degradation. 45. The conjugate of claim 38, wherein the antisense oligonucleotide prevents proteins or nucleic acids from binding to at least a portion of the 3′UTR of a DMPK transcript. 46. The conjugate of claim 38, wherein the antisense oligonucleotide prevents a protein or nucleic acid from binding to any one of SEQ ID NOs: 24-27. 47. The conjugate of claim 38, wherein the antisense oligonucleotide comprises two wing portions, each of which flank the central portion. 48. The conjugate of claim 47, wherein each of the two wing portions comprises at least 3 nucleotides. 49. The conjugate of claim 47, wherein each of the two wing portions is of differing length. 50. The conjugate of claim 47, wherein each of the two wing portions comprises at least 3 nucleotides modified to increase stability or specificity of the oligonucleotide. 51. The conjugate of claim 50, wherein each of the two wing portions comprises unmodified and/or modified nucleotides. 52. The conjugate of claim 38, wherein the ratio of antisense oligonucleotide conjugated per antibody or antigen binding fragment is 1:1. 53. The conjugate of claim 38, wherein the conjugate is capable of penetrating muscle cells. 54. The conjugate of claim 38, wherein the conjugate further comprises a muscle blind polypeptide (MBNL1), or a functional fragment thereof comprising all four zinc finger motifs, interconnected to the antibody or antigen fragment thereof. 55. A method of treating myotonic dystrophy, comprising administering to a patient in need thereof a conjugate of claim 38. 56. A method of promoting entry into muscle cells, comprising contacting cells or administering to a patient a conjugate of claim 38.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (101)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Armstrong, Dustin D., Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.